About KRS Pharmaceuticals
KRS Pharmaceuticals is a Healthcare company based in Hyderabad (India) by Narendra Balusu and Lakshmana Swamy Balusu. It manufactures chemicals and intermediates while providing contract research services for the pharmaceutical industry. It operates on a B2B model. The company has 55 employees. Its Indian entity Krs Pharmaceuticals Private Limited reported revenue of ₹54.79 Cr. Its focus areas include Pharmaceuticals, Manufacturing and Chemical Intermediates. Its competitors include Pharmaron, Lonza, Pfizer, Boehringer Ingelheim and LabConnect and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
KRS Pharmaceuticals operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and chemical intermediates. Manufactures chemicals and intermediates while providing contract research services for the pharmaceutical industry. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
- Headquarters Hyderabad, India
- Employees 55
- Founders Narendra Balusu, Lakshmana Swamy Balusu
- SectorsHealthcare
- Website krspharma.com/cgi-sys/suspendedpage.cgi
- Legal Name Krs Pharmaceuticals Private Limited
- Date of Incorporation 12 Sep, 2000
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹54.79 Cr
FY 2025 · +60% YoY
- Net Profit₹16.1 Lakh
FY 2025 · 0% margin
- EBITDA₹3.27 Cr
FY 2025 · 6% margin
- Employee Count55
Associated legal entities of KRS Pharmaceuticals
KRS Pharmaceuticals operates through Krs Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Krs Pharmaceuticals Private Limited CIN U24239TG2000PTC035234 | Active | 12 Sep 2000 | Hyderabad, Telangana | ₹54.8 Cr | 55 | 4 | View details |
Board of directors of Krs Pharmaceuticals Private Limited (KRS Pharmaceuticals)
Krs Pharmaceuticals Private Limited is the primary company behind KRS Pharmaceuticals. The board of Krs Pharmaceuticals Private Limited currently have 4 directors; the longest-serving is Lakshmana Swamy Balusu, appointed in 2000. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Lakshmana Swamy Balusu DIN 01284990 | Managing Director | 12 Sep 2000 | 26 yrs 1 mo | Krs Pharmaceuticals Private Limited |
| Narendra Balusu DIN 00378980 | Director | 27 Aug 2004 | 22 yrs 1 mo | Krs Pharmaceuticals Private Limited |
| Koneru Chiranjivee Rammohan Rao DIN 02848093 | Director | 02 Nov 2009 | 16 yrs 11 mo | Krs Pharmaceuticals Private Limited |
| Sai Phani Teja Balusu DIN 08723271 | Director | 13 Oct 2021 | 5 yrs | Krs Pharmaceuticals Private Limited |
People of KRS Pharmaceuticals
2 people are tracked at KRS Pharmaceuticals (2 in leadership); the tracked headcount is 55.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
| Co-Founder, Managing Director | Leadership |
Complete people profiles for KRS Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of KRS Pharmaceuticals
Figures of Krs Pharmaceuticals Private Limited, the primary company behind KRS Pharmaceuticals, for FY 2025. Revenue was ₹54.79 Cr (+60% year on year). Net profit was ₹16.1 Lakh (0% margin). EBITDA was ₹3.27 Cr (6% margin). Revenue has grown at a compounded annual rate of 0% over three years and +1% over five years.
- ₹54.79 CrRevenue · FY 2025 · +60% YoY
- ₹16.1 LakhNet profit · 0% margin
- ₹3.27 CrEBITDA · 6% margin
- ₹6.73 CrPaid-up capital
- 55Employees (provident fund records)
- 0%Revenue CAGR, 3 years
- +1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Krs Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for KRS Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of KRS Pharmaceuticals
KRS Pharmaceuticals has 9 listed competitors in our database, 6 of them funded. They include Pharmaron, Lonza, Pfizer, Boehringer Ingelheim and LabConnect, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pharmaron.com | 2003 | Beijing, China | $320M | 476 | Drug discovery and development services for small molecules are provided. | |
| lonza.com | 1897 | Basel, Switzerland | $100,000 | 14,500 | CDMO services for pharma, biotech, and specialty ingredients are provided. | |
| pfizer.com | 1849 | New York, United States | $8M | – | Pharmaceutical products for treating multiple diseases are provided. | |
| boehringer-ingelheim.com | 1885 | – | – | 31 | Generic drugs and clinical research services are provided globally. | |
| labconnect.com | 2002 | Johnson, United States | $28.5M | – | Laboratory testing, clinical trial research, and biopharma services are provided. | |
| dotmatics.com | 2005 | – | $11.34M | 512 | AI powered scientific data management and workflow automation solutions | |
| ainos.com | 1986 | San Diego, United States | – | 43 | Novel point-of-care testing and low-dose interferon therapeutics are developed. | |
| biomatter.ai | 2018 | Vilnius, Lithuania | $7.73M | – | Provider of synthetic biology and AI-based technology for generative protein design | |
| betadrugslimited.com | 2005 | Panchkula, India | – | 637 | Developer of therapeutics for oncology and dermatology |
Detailed competitors of KRS Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as KRS Pharmaceuticals (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about KRS Pharmaceuticals
KRS Pharmaceuticals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
KRS Pharmaceuticals has 55 employees.
The primary company behind KRS Pharmaceuticals, Krs Pharmaceuticals Private Limited, reported revenue of ₹54.79 Cr for FY 2025, up 60% year on year.
KRS Pharmaceuticals operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and chemical intermediates. Manufactures chemicals and intermediates while providing contract research services for the pharmaceutical industry. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
KRS Pharmaceuticals operates through Krs Pharmaceuticals Private Limited.
The legal entities of KRS Pharmaceuticals currently have 4 directors, including Lakshmana Swamy Balusu, Narendra Balusu, Sai Phani Teja Balusu and others.